Quantcast

The Chronic Kidney Disease (CKD) Drug Market Will Increase to $11.7 Billion in 2022, Driven by the Uptake of Novel Agents

January 28, 2014

The CKD Market Will Decline Through 2017, Due to Genericization of Expensive Agents and Reimbursement Constraints in the U.S., According to Findings from Decision Resources Group

BURLINGTON, Mass., Jan. 28, 2014 /PRNewswire/ — Decision Resources Group finds that, after an initial decline driven by generic and biosimilar competition in the G7 markets and changes in reimbursement practices in the United States, the total chronic kidney disease (CKD) market will return to growth, achieving total sales of $11.7 billion in 2022 compared with $11 billion in 2012. This market forecast includes erythropoietin-stimulating agents (ESAs), phosphate binders, calcium mimetics, active vitamin D analogues, antihypertensive agents, IV irons and emerging CKD therapies for the CKD non-dialysis and dialysis patient populations.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36768LOGO)

Other key findings from the Pharmacor Chronic Kidney Disease report:

    --  ESAs, a dominant presence in the CKD-associated anemia market, will come
        under pressure from the launch of novel biosimilars in all markets and
        an increasingly hostile reimbursement environment in the United States.
        Although the ESAs will retain the largest market share in 2022, this
        will have diminished significantly compared with the start of the
        2012-2022 forecast period.
    --  The launch and uptake of novel drugs during the next ten years will be
        the largest driver of market growth. Of the emerging therapies with
        novel mechanisms of action, the hypoxia-inducible factor-prolyl
        hydroxylase (HIF-PH) inhibitors will have the biggest impact on the CKD
        market.
    --  Based on their potential to offer a lower-cost, safer, orally
        administered alternative to ESAs--HIF-PH inhibitors--should capture
        considerable sales by 2022, with FibroGen/AstraZeneca/Astellas's
        roxadustat forecast to launch as first-in-class in 2018.
    --  Other agents in development include AbbVie's atrasentan for diabetic
        nephropathy and Amgen's velcalcetide, an IV calcium mimetic, which will
        provide an alternative to cincalcet (Amgen's Sensipar/Mimpara, Kyowa
        Hakko Kirin's Regpara) for CKD patients with secondary
        hyperparathryoidism.

Comments from Decision Resources Group Director Matthew Scutcher, Ph.D.:

    --  "Hypertension, diabetes and an aging population are key drivers behind a
        forecasted increase in patients with CKD in all seven major markets
        under study, which further increases the opportunities in this disease
        area."
    --  "Unfortunately, most products in late-stage development do not treat the
        underlying condition but most do offer some advantages over existing
        agents and thus should compete strongly in the marketplace."

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group

Christopher Comfort

781-993-2597

ccomfort@dresourcesgroup.com

SOURCE Decision Resources Group


Source: PR Newswire



comments powered by Disqus